Frontiers in microbiology
Cure8 research brief
Why This Matters
This preclinical study reports that an extract of Anacyclus pyrethrum reduced colitis signs in a mouse DSS model and was linked to improved intestinal barrier markers, lower innate immune receptor expression, changes in gut bacteria, and altered fecal metabolites.
These mechanistic findings could inform early-stage research into botanical agents for IBD.
Who Should Pay Attention
Researchers (natural products, microbiome, barrier biology), translational scientists, and clinicians following preclinical IBD research.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This study used a DSS-induced colitis mouse model to test whether an aqueous extract of Anacyclus pyrethrum (AP) affects intestinal inflammation, barrier proteins, gut bacteria, and fecal metabolites.
The authors report that AP-treated mice showed reduced clinical signs of colitis, lower expression of innate immune receptors TLR4 and TLR9, higher levels of tight-junction proteins (occludin and ZO-1), shifts in gut microbiota (including higher Bacteroides and some Clostridiales), and changes in fecal metabolic profiles.
The work is preclinical: it was performed in mice using a chemical colitis model (DSS), not in people. Findings show biological associations (barrier proteins, receptor expression, microbiome composition, metabolites) rather than clinical safety or efficacy in humans.
For patients this suggests a potential mechanistic signal that components of AP might modulate immune signaling, barrier integrity, and the microbiome in an animal model of colitis. However, this does not mean AP is safe or effective for people with IBD; clinical studies would be needed.
Keep In Mind
Findings come from a DSS mouse model (preclinical) reported in an abstract/full-text on Europe PMC; results are mechanistic and exploratory and do not establish safety or efficacy in humans.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFrontiers in microbiology
AuthorsWu J, Wang Q, Mao X
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedJul 14, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Protective effects of Brassica rapa L. water extract against DSS-induced acute UC-like colitis in mice and its regulatory mechanisms involving gut microbiota and the intestinal mucosal barrier
The study identifies a plant extract that reduced colitis-like injury in mice and altered gut microbes and intestinal barrier markers, which could inform future preclinical work. For people with IBD, this is early-stage...
Cyanidin-3-O-glucoside Alleviates Inflammatory Bowel Disease by Targeting the NF-κB Pathway and is Associated With Alterations in 1-DNJ.
This preclinical study suggests cyanidin-3-O-glucoside (a dietary anthocyanin) can reduce inflammation and modify gut microbes and metabolites in an experimental colitis model by inhibiting NF-κB signaling. It points to...
Dendrobium huoshanense polysaccharides alleviate DSS-induced ulcerative colitis in mice: comparison between different parts of plant and role of GLP-1/GLP-1R axis.
This study identifies a plant-derived polysaccharide (from the stem of Dendrobium huoshanense) that reduced inflammation and tissue injury in a mouse model of ulcerative colitis and points to GLP-1 signaling as a likely...